SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
CollPlant Biotechnologies Ltd.
Ordinary Shares, par value NIS 1.5 per share
Ordinary Shares represented by American Depositary Shares (ADSs) at a ratio of one Ordinary Share per ADS)
of Class of Securities)
Jonathan M. Nathan, Adv.
Meitar Liquornik Geva Leshem Tal
16 Abba Hillel Road Street,
Ramat Gan 5250608, Israel
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
August 6, 2019
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
*The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).
|CUSIP No. 19516R107|
Names of Reporting Persons
Check the Appropriate Box if a Member of a Group
(See Instructions) (a) ☐
SEC USE ONLY
Source of Funds (See Instructions)
Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
Citizenship or Place of Organization
Sole Voting Power
1,140,300 Ordinary Shares(1) (2)
Shared Voting Power
Sole Dispositive Power
1,140,300 Ordinary Shares(1) (2)
Shared Dispositive Power
Aggregate Amount Beneficially Owned by Each Reporting Person
1,140,300 Ordinary Shares(1) (2)
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
Percent of Class Represented by Amount in Row (11)
Type of Reporting Person (See Instructions)
|(1)||As reported by the Issuer, effective as of July 15, 2019, the Issuer effected a 1-for-50 reverse split of its outstanding ordinary shares, which proportionately raised the par value per ordinary share from NIS 0.03 to NIS 1.5, and caused a corresponding adjustment of the ratio of the number of ordinary shares to American Depositary Shares (“ADSs”) from 50:1 to 1:1 (since the ADSs were otherwise unaffected by that reverse share split). All numbers appearing in this Amendment No. 2 to Schedule 13D are presented on a post-reverse split basis.|
|(2)||Includes an aggregate of 186,000 Ordinary Shares issuable upon exercise of ordinary warrants that are currently exercisable.|
|(3)||Based on 3,820,789 Ordinary Shares issued and outstanding as of August 6, 2019 (which number was provided by the Issuer to the Reporting Person upon the request of the Reporting Person), as adjusted to reflect the potential issuance of shares pursuant to the exercise of warrants held by the Reporting Person as described in footnote (2) above.|
Item 1. Security and Issuer.
This Amendment No. 2 (this “Amendment No. 2”) to the Statement of Beneficial Ownership on Schedule 13D filed on February 11, 2019 (the “Statement”), as amended by Amendment No. 1 thereto, filed on June 20, 2019 (“Amendment No. 1”), relates to the ordinary shares, par value 1.5 New Israeli Shekels (“NIS”) per share (“Ordinary Shares”) (including Ordinary Shares represented by American Depositary Shares (“ADSs”) at a ratio of one Ordinary Share per ADS) of Collplant Biotechnologies Ltd., an Israeli company (the “Issuer”). The principal executive offices of the Issuer are located at 4 Oppenheimer Street, Weizmann Science Park, Rehovot 7670104, Israel.
After the filing of Amendment No. 1, on July 15, 2019, the Issuer effected a 1-for-50 reverse split of its outstanding Ordinary Shares, which proportionately raised the par value per Ordinary Share from NIS 0.03 to NIS 1.5, and caused a corresponding adjustment of the ratio of the number of Ordinary Shares to ADSs from 50:1 to 1:1 (since the ADSs were otherwise unaffected by that reverse share split). All numbers appearing in this Amendment No. 2 to Schedule 13D are presented on a post-reverse split basis.
This Amendment No. 2 is being filed by the Reporting Person (as defined in Item 2 below) in order to report the purchase by the Reporting Person, on August 6, 2019, of an additional 140,000 ADSs (which represent an equivalent number of Ordinary Shares), which purchase has increased the Reporting Person’s beneficial ownership by in excess of 1% of the outstanding Ordinary Shares since the filing of Amendment No. 1.
Item 2. Identity and Background.
|(a)||Name:||This Amendment No. 2 is being filed by Ami Sagy, an individual (the “Reporting Person”).|
|(b)||Residence or Business Address: 66 Pinkas Street, Tel Aviv, Israel 62157.|
|(c)||Present Principal Occupation/Employment: The Reporting Person serves as manager of the Sagy Group, which manages bank charges and reduces financial costs for medium to large organizations and institutions. The principal address of the offices at which the Reporting Person is employed is 84 Ben-Tzvi Road, Tel Aviv 68104, Israel.|
|(d)||Criminal Proceedings: During the last five years, the Reporting Person has not been convicted in any criminal proceeding.|
|(e)||Civil Proceedings Involving Securities Law Violations: During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, as a result of which he is or was subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.|
Item 3. Source and Amount of Funds or Other Consideration.
The Reporting Person utilized his personal funds in acquiring the Ordinary Shares reported in this Amendment No. 2.
Item 4. Purpose of Transaction.
The Reporting Person has acquired the Ordinary Shares reported herein for investment purposes only. The Reporting Person may, from time to time, based on various factors, acquire additional Ordinary Shares of the Issuer or sell Ordinary Shares, on the open market or in privately negotiated transactions.
Except as described above, as of the filing of this Amendment No. 2, the Reporting Person does not have any definitive plans or proposals which relate to or would result in any of the following: (a) the acquisition by the Reporting Person of additional Ordinary Shares (except for an additional 186,000 Ordinary Shares that may be issued to the Reporting Person upon exercise of warrants held by the Reporting Person that have not yet been exercised, which Ordinary Shares are already included in his beneficial ownership), or the disposition of Ordinary Shares that he holds; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) a change in the present board of directors or management of the Issuer, including any plan or proposal to change the number or term of directors or to fill any existing vacancies on the board; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer’s business or corporate structure; (g) changes in the Issuer’s memorandum of association or articles of association or other actions which may impede the acquisition of control of the Issuer by any person; (h) causing the ADSs to be delisted from the NASDAQ Capital Market or any other national securities exchange on which they may be listed in the future, or to cease to be authorized to be quoted in any inter-dealer quotation system of a registered national securities association in which they may be quoted in the future; (i) causing the ADSs to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) any action similar to any of those enumerated above.
Item 5. Interest in Securities of the Issuer.
All calculations of beneficial ownership percentage in this Amendment No. 2 are made on the basis of 3,820,789 Ordinary Shares issued and outstanding as of August 6, 2019 (which number was provided by the Issuer to the Reporting Person at the request of the Reporting Person), as adjusted to reflect the potential issuance of additional Ordinary Shares pursuant to the exercise of warrants held by the Reporting Person as described in paragraph (a) below.
(a) The Reporting Person beneficially owns 1,140,300 Ordinary Shares of the Issuer, constituting approximately 28.5% of the issued and outstanding share capital of the Issuer, consisting of (i) 954,300 Ordinary Shares (represented by 954,300 ADSs) held directly by the Reporting Person, plus (ii) an additional 186,000 Ordinary Shares issuable upon exercise of warrants held by the Reporting Person that have not yet been exercised, all of which are currently exercisable.
(b) The Reporting Person possesses sole power to vote and direct the vote, and sole power to dispose or to direct the disposition of, all of the Ordinary Shares that he currently beneficially owns.
(c) During the 60 days preceding the date of this Amendment No. 2, the Reporting Person effected the following purchases of Ordinary Shares (all of which were effected in Ordinary Shares represented by ADSs):
|Type of Transaction and Date||Quantity of Ordinary Shares/ ADSs Purchased||Price Paid Per ADS|
|Open-Market Purchases of ADSs on NASDAQ Capital Market:|
|August 6, 2019||140,000 Shares/140,000 ADSs||$3.50 per ADS|
(d) Not applicable.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
Under the warrants referenced in paragraph (a) of Item 5 above, the Reporting Person has the right to acquire 186,000 Ordinary Shares, at an exercise price of 40 New Israeli Shekels (approximately US $11.50) per Ordinary Share (all of such warrants are currently exercisable). Those warrants expire in December 2022.
Item 7. Material to be Filed as Exhibits.
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|/s/ Ami Sagy|
Dated: August 12, 2019